Overview

• Hims & Hers continued offering unapproved compounded versions of semaglutide even after February’s end to the FDA-declared GLP-1 shortage, prompting the split.
• The drugmaker accused the telehealth company of mass compounding under the false guise of personalization and deceptive marketing that risked patient safety.
• Hims & Hers shares plunged more than 20% in premarket trading on June 23 as investors reacted to the abrupt termination of direct Wegovy access.
• Novo Nordisk’s internal investigation and a Brookings Institution report found that many compounding suppliers in China lacked FDA inspections or had quality violations.
• Hims & Hers CEO Andrew Dudum alleged that Novo Nordisk was misleading the public and pressuring the company to steer patients toward branded Wegovy.